Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Cytometry B Clin Cytom ; 98(5): 441-448, 2020 09.
Article in English | MEDLINE | ID: mdl-31692239

ABSTRACT

BACKGROUND: The role of CD200 in the differential diagnosis of chronic lymphocytic leukemia (CLL) and classical mantle cell lymphoma (MCL) is well established. Its role in the differential diagnosis of CLL and other lymphoproliferative disorders (LPD) is less clear, in particular its positive predictive value (PPV). MATERIALS AND METHODS: We conducted a systematic review of the use of CD200 in the differential diagnosis of CLL, MCL, and other predominantly leukemic, typically CD103-negative LPD. With the results, we then derived a curve to determine the PPV based on the prevalence of the disorders included in the differential diagnosis. RESULTS: Of 43 publications screened, 27 were included in the systematic review (5,764 patients). The median CD200 positivity rate in all studies and the percentage of CD200-positive (pooled) patients was 100% and 95% (3,061/3,208) in CLL, 4 and 8% (86/1112) in MCL and 56 and 62% (425/689) in other LPD. CONCLUSION: CD200 is suboptimal for the differential diagnosis of CLL and disorders other than nodal MCL.


Subject(s)
Antigens, CD/genetics , Diagnosis, Differential , Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis , Lymphoma, Mantle-Cell/diagnosis , Lymphoproliferative Disorders/diagnosis , Biomarkers, Tumor/genetics , Female , Flow Cytometry/methods , Gene Expression Regulation, Leukemic/genetics , Humans , Immunophenotyping/methods , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Lymphoma, Mantle-Cell/genetics , Lymphoma, Mantle-Cell/pathology , Lymphoproliferative Disorders/genetics , Lymphoproliferative Disorders/pathology , Male , Predictive Value of Tests
2.
Lab Med ; 51(4): 385-393, 2020 Jul 08.
Article in English | MEDLINE | ID: mdl-31834933

ABSTRACT

BACKGROUND: Differences between follicular lymphoma (FL) and diffuse large B-cell lymphoma/high-grade B-cell lymphoma (DLBCL/HGBL) by flow cytometry are underexplored. METHODS: We retrospectively assessed flow cytometry results from 191 consecutive lymph node biopsies diagnosed with FL or DLBCL/HGBL. RESULTS: The only parameters that differed between the 2 groups in the derivation cohort were forward scatter and side scatter (P < 10-6; area under the curve [AUC], 0.75-0.8) and %CD23 (P = .004; area under the receiver characteristic operating curve, 0.64). However, since light scatter characteristics did not distinguish between grade 3 FL and DLBCL/HGBL, we set out to develop a model with high sensitivity for the exclusion of the latter. Several models, including FS and %CD23, were tested, and 2 models showed a sensitivity of >0.90, with negative predictive values of ≥0.95, albeit with low specificity (0.45 to 0.57). CONCLUSION: Two simple models enable the exclusion of DLBCL/HGBL with a high degree of confidence.


Subject(s)
Flow Cytometry/methods , Lymph Nodes/pathology , Lymphoma, Follicular/diagnosis , Lymphoma, Large B-Cell, Diffuse/diagnosis , B-Lymphocytes/metabolism , B-Lymphocytes/pathology , Data Interpretation, Statistical , Diagnosis, Differential , Flow Cytometry/standards , Humans , Liquid Biopsy/methods , Liquid Biopsy/standards , Neprilysin/metabolism , Sensitivity and Specificity
3.
Blood Coagul Fibrinolysis ; 30(7): 364-365, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31464688

ABSTRACT

: Vitamin K antagonists (VKA) remain the treatment of choice for catastrophic antiphosphilipid syndrome (CAPS). However, when VKAs do not work for a specific patient, direct oral anticoagulants (DOAC) may be a valid therapeutic alternative. We present a patient with a psychiatric disorder and CAPS who was noncompliant to VKA and low-molecular-weight heparin. He was started on dabigatran and has remained thrombosis-free for 8 years. Due to CAPS he has developed progressive renal failure but dabigatran levels were within the expected range. In conclusion, this case report provides anecdotic evidence that dabigatran may be of use in patients with high-risk APS in whom VKA are not an option.


Subject(s)
Antiphospholipid Syndrome/drug therapy , Dabigatran/therapeutic use , Anticoagulants/therapeutic use , Catastrophic Illness , Factor Xa Inhibitors/therapeutic use , Humans , Male , Treatment Outcome , Vitamin K/antagonists & inhibitors
6.
Leuk Res ; 73: 24-28, 2018 10.
Article in English | MEDLINE | ID: mdl-30193204

ABSTRACT

Myelodysplastic syndrome (MDS) and antithrombotic medication both increase the risk of bleeding. We set out to analyze the prevalence of use, indications and bleeding risk of antithrombotic therapy in patients with MDS in a retrospective, single-center study including all patients with MDS with >20 × 109/L platelets. 193 patients (59% male, median age 75 years) were included; 122 did not receive antithrombotic treatment, 51 received antiplatelet agents and 20 received anticoagulants. The cumulative incidence of major bleeding was higher in both the antiplatelet group (11.8% at 4 years, 95% confidence interval [95%CI]: 4.7-22.3%) and the anticoagulation group (21.2% at 4 years, 95%CI 6-42.5%) than in the control group (2.8% at 4 years 95%CI: 0.7-7.3%). The prevalence of use of antithrombotic medication in this cohort of patients with MDS was high and bleeding risk was increased in these patients.


Subject(s)
Anticoagulants/adverse effects , Fibrinolytic Agents/adverse effects , Hemorrhage/chemically induced , Hemorrhage/mortality , Myelodysplastic Syndromes/mortality , Aged , Aged, 80 and over , Anticoagulants/administration & dosage , Female , Fibrinolytic Agents/administration & dosage , Hemorrhage/drug therapy , Humans , Incidence , Male , Middle Aged , Myelodysplastic Syndromes/drug therapy , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...